PRESSEMITTEILUNGEN

New York (ots/PRNewswire) – Berg Pharma, ein Pharmaunternehmen mit Sitz in Boston, das sich auf die Erforschung und Entwicklung neuer Therapien zur Behandlung von Krebs- und Stoffwechselerkrankungen konzentriert, hat den Beginn einer neuen klinischen Studie mit dem Titel ?Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in [...]

Continue reading

Adult Patients, Alopezie, Bpm, Breast Cancer, Dose Escalation Study, Dr Med, Kettering Cancer Center, Klinische Studie, Memorial Sloan Kettering, Memorial Sloan Kettering Cancer Center, Miller School, Ots, Pharmacokinetics, Prnewswire, Safety Tolerability, School Of Medicine, Sloan Kettering Cancer, Sloan Kettering Cancer Center, Treatment Of Breast Cancer, University Of Miami Miller School Of Medicine

——————————————————————————– Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. ——————————————————————————– Forschung/Entwicklung/Schwere Blutvergiftung Heidelberg (euro adhoc) – Planegg/München und US-Standorte in Princeton, NJ, und Houston, TX, 12. Januar 2011 – Die Agennix AG (Frankfurter Wertpapierbörse: AGX) gab heute bekannt, dass neue und detailliertere Daten einer Phase II-Studie mit Talactoferrin bei schwerer [...]

Continue reading

Adhoc, Agennix, Cardiac Dysfunction, Cause Mortality, Corporate News, Critical Care Medicine, Frankfurter, Heidelberg, Infectious Disease, Kalifornien, Kongress, Krebs, Pharmacokinetics, Phase Ii, Placebo, Princeton Nj, Schwere, Sepsis, Septic Shock, Society Of Critical Care Medicine

Study to include healthy volunteers and diabetic patients ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information Subtitle: Study to include healthy volunteers and diabetic patients Berlin, Germany, 7 July 2010 (euro adhoc) – NOXXON Pharma AG announced today that it has permission [...]

Continue reading

Adhoc, Berlin Germany, Clinical Trial, Clinicaltrials Gov, Corporate News, Diabetic Nephropathy, Diabetic Patients, Double Blind Placebo, Dr Frank, Endpoints, Frank Morich, Monocyte Chemoattractant Protein, Nox, Noxxon, Pharmacodynamic, Pharmacodynamics, Pharmacokinetic, Pharmacokinetics, Phase Ib, Safety Tolerability

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information Berlin, Germany, May 03, 2010 (euro adhoc) – NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful completion of [...]

Continue reading

Adhoc, Berlin Germany, Biopharmaceutical Company, Chief Executive Officer, Clinicaltrials Gov, Dr Frank, Frank Morich, Hematological Malignancies, Information Berlin, Intravenous Administration, Novel Drugs, Nox, Noxxon, Pharmacodynamics, Pharmacokinetics, Safety Tolerability, Sdf, Stromal Cell, Study Goal, Wbc

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information Berlin, Germany, November 02, 2009 (euro adhoc) – NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful initial dosing [...]

Continue reading

Berlin Germany, Biopharmaceutical Company, Chief Executive Officer, Clinical Stage, Clinicaltrials Gov, Drug Candidate, Efficacy Data, Frank Morich, Information Berlin, Intravenous Administration, Novel Drugs, Nox, Noxxon, Pharmacodynamics, Pharmacokinetics, Safety Profile, Safety Tolerability, Stage Of Development, Trial Application, Unmet Medical Need

(pressebox) Berlin, 12.10.2009, NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, today announced successful completion of the first phase I trial with its antiinflammatory Spiegelmer® NOX-E36. This drug candidate will be developed for the treatment of complications of type 2 diabetes, preferentially diabetic [...]

Continue reading

Animal Models, Biopharmaceutical Company, Diabetes Patients, Diabetic Nephropathy, Double Blind Placebo, Drug Candidate, Gender Differences, Inflammatory Reaction, Intravenous Doses, Monocyte Chemoattractant Protein, Novel Drugs, Noxxon, Pharmacodynamic, Pharmacodynamics, Pharmacokinetics, Plasma Concentrations, Safety Tolerability, Subcutaneous Doses, Target, Type 2 Diabetes

Good safety and pharmacodynamic profile and additional good subcutaneous bioavailability ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information Utl.: Good safety and pharmacodynamic profile and additional good subcutaneous bioavailability = Berlin, Germany, 12 October 2009 (euro adhoc) – NOXXON Pharma AG, the [...]

Continue reading

Animal Models, Berlin Germany, Biopharmaceutical Company, Diabetic Nephropathy, Double Blind Placebo, Drug Candidate, Gender Differences, Intravenous Doses, Monocyte Chemoattractant Protein, Novel Drugs, Noxxon, Pharmacodynamic, Pharmacodynamics, Pharmacokinetics, Plasma Concentrations, Reac, Safety Tolerability, Subcutaneous Doses, Target, Type 2 Diabetes

(pressebox) Aachen, 05.10.2009, Das biopharmazeutische Unternehmen PAION AG (ISIN DE000A0B65S3; Frankfurter Wertpapierbörse, Prime Standard: PA8) gibt heute bekannt, dass der wissenschaftliche Abstract ‘A Phase I SAD Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of CNS 7056′ (‘Eine Phase-I-SAD-Studie zur Bewertung der Sicherheit, Pharmacokinetik und Pharmacodynamik von CNS 7056′) für einen Vortrag bei der ‘Best Abstracts [...]

Continue reading

Abstract, Asa Annual Meeting, Celebration, Editors, Frankfurter, Isin, Klinischen, Morial Convention Center, New Orleans, Paion Ag, Pharmacodynamics, Pharmacokinetics, Prime Standard, Wolfgang

Barcelona, Spain (ots/PRNewswire) – – Data Shows Potential Tolerability Advantage for Pitavastatin Compared With Other Statins New data presented at the European Society of Cardiology congress (ESC) demonstrated that the co-administration of the cytochrome inhibitor itraconazole has no clinically relevant effect on the pharmacokinetics of pitavastatin, in healthy volunteers. Many of the existing statins such [...]

Continue reading

Atorvastatin, Barcelona Spain, Cyp3a4 Inhibitors, Drug To Drug Interaction, European Society Of Cardiology, European Society Of Cardiology Congress, Grapefruit Juice, Hospitalised, Itraconazole, Muscle Problems, Pathway, Pharmacokinetics, Pitavastatin, Plasma Concentrations, Prnewswire, Relevant Effect, Simvastatin, Statins, Volunteers

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– investments Berlin/Jena, Germany, 8 June 2009 (euro adhoc) – NOXXON Pharma AG (NOXXON), an investment holding of Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG (DEWB), announced today the successful initial dosing of healthy volunteers with Spiegelmer® NOX-E36 in [...]

Continue reading

Adhoc, Bertram, Biotechnology Companies, Chief Executive Officer, Clinical Stage, Deputy Chairman, Dr Frank, E36, Frank Morich, Health Product, Human Clinical Trial, Jena Germany, Management Board, Nephropathy, Noxxon, Pharmacokinetics, Stage Company, Subcutaneous Administration, Supervisory Board, Trial Application